big insiders buying
ooops....TRMS will be hot hot hot :
Such response rates have never been attained in clinical trials of HIV patients living with drug-resistant virus. FUZEON, co-developed by Roche and Trimeris (Nasdaq: TRMS - News), is the first and only fusion inhibitor available for the treatment of HIV. MK-0518 is a novel investigational integrase inhibitor being developed by Merck & Co., Inc.
These findings are consistent with the recent HIV treatment guidelines, which emphasize undetectability as the goal of therapy in treatment-experienced patients, as well as the need to initiate multiple active anti-HIV agents simultaneously in order to achieve this goal.
Administered via one 90 mg injection twice-daily, FUZEON is the first and only fusion inhibitor for the treatment of HIV. Unlike other HIV drugs that work after HIV has entered the human immune cell, FUZEON works outside the CD4 cell, blocking HIV from entering the cell. For this reason, FUZEON is effective in treatment-experienced patients who have developed resistance to other anti-HIV drugs
FUZEON is indicated for use in combination with other antiretroviral agents for the treatment of HIV in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
http://biz.yahoo.com/bw/061005/200610050...
UP NICELY !!!! LOOKS LIKE $9 IS IN PLAY !!!! REASON:
--Press Release Source: Trimeris, Inc.
Trimeris Reports First Quarter 2007 FUZEON(R) Sales Results
Tuesday April 17, 4:00 pm ET
-- Global sales in the first quarter grew 16 percent over 2006
-- U.S/Canada sales in the first quarter grew 7 percent over 2006
-- Ex U.S/Canada sales in the first quarter grew 25 percent over 2006
MORRISVILLE, N.C.--(BUSINESS WIRE)--Trimeris, Inc. (NASDAQ: TRMS - News) today announced worldwide net sales of FUZEON for the first quarter of 2007 were $64.3 million, an increase of 16 percent from $55.4 million in the first quarter of 2006. Net sales of FUZEON in the U.S. and Canada for the first quarter of 2007 were $29.3 million, up 7 percent from $27.4 million in the first quarter of 2006. Net sales of FUZEON outside the U.S. and Canada for the first quarter of 2007 were $35.0 million, an increase of 25 percent from $28.0 million in the first quarter of 2006. All sales of FUZEON are recorded by F. Hoffmann-La Roche Ltd, ("Roche"), Trimeris' collaborative partner.
"We are pleased with the overall growth that FUZEON continues to generate. In North America, as seen in prior years, first quarter sales decreased from the fourth quarter, partially due to wholesaler stocking during the fourth quarter. Inventory levels at the U.S wholesalers have returned to normal levels during the first quarter. For the full year of 2007, we look forward to worldwide FUZEON sales growth," said E. Lawrence Hill, Acting President and Chief Operating Officer of Trimeris.
The release of complete financial results for the first quarter of 2007 will take place in early May, 2007.
Net Fuzeon Sales
The table below presents net FUZEON sales by quarter beginning in the first quarter of 2005:
(millions)
2005
--------------------------------
Q1 Q2 Q3 Q4 Total
--------------------------------
U.S/Canada Net Sales $23.3 $25.2 $28.4 $35.8 $112.7
Ex. U.S/Canada Net Sales 19.1 28.7 20.5 27.1 95.5
--------------------------------
Global Net Sales $42.5 $53.9 $48.9 $62.9 $208.2
================================
(numbers may not add due to rounding)
(millions)
2006 2007
------------------------------- ------
Q1 Q2 Q3 Q4 Total Q1
------------------------------- ------
U.S/Canada Net Sales $27.4 $31.1 $33.5 $42.2 $134.2 $29.3
Ex. U.S/Canada Net Sales 28.0 26.2 29.5 31.1 114.8 35.0
------------------------------- ------
Global Net Sales $55.4 $57.2 $63.0 $73.3 $249.0 $64.3
=============================== ======
(numbers may not add due to
rounding)
--April 17 (Reuters) - Biopharmaceutical company Trimeris Inc. (TRMS.O: Quote, Profile , Research) said first-quarter net sales of its HIV drug Fuzeon rose 16 percent.
In a statement, the company said worldwide net sales of Fuzeon were $64.3 million in the latest quarter, compared with $55.4 million in the year-ago quarter.
--